Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis.

Abstract

A randomized, double-blind, left-right study to compare the therapeutic efficacy of hydrocortisone 17-butyrate (Locoid) 0.1% cream with hydrocortisone (Uniderm) 1% cream was performed in forty children suffering from atopic dermatitis. The medications were applied to symmetrical bilateral skin lesions twice daily for a maximum of 4 weeks or until complete clinical clearance of such lesions had occurred. Complete clearance of skin symptoms was found in 36% of the Locoid-treated sides and in 23% of the Uniderm-treated sides following 2 weeks of therapy and in 60% and 30%, respectively, after 4 weeks of treatment. This difference in clearance rate after 4 weeks between both preparations was significantly in favour of Locoid cream. The expressed preferences of patients/parents and investigator were also significantly in favour of Locoid cream, both after 2 and 4 weeks. No serious side-effects were reported during this study. It is concluded that Locoid cream is significantly superior to Uniderm cream in the treatment of atopic dermatitis in children.

• Authors: N K Veien, T Hattel, O Justesen, A Nørholm, H L Verjans
• Journal: The Journal of international medical research (J Int Med Res) Vol. 12 Issue 5 Pg. 310-3 ( 1984) ISSN: 0300-0605 [Print] England
• PMID: 6389217 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• hydrocortisone-17-butyrate
• Hydrocortisone

Topics

• Administration, Topical
• Anti-Inflammatory Agents (therapeutic use)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Dermatitis, Atopic (drug therapy)
• Double-Blind Method
• Female
• Humans
• Hydrocortisone (analogs & derivatives, therapeutic use)
• Infant
• Male
• Random Allocation
• Time Factors